- Home
- MOBX vs ALGS Comparison
MOBX vs ALGS Comparison
Compare MOBX & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOBX | ALGS |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 57.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MOBX | ALGS |
|---|---|---|
| Price | $0.54 | $13.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 938.3K | 81.5K |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,984,000.00 | $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 180.13 | N/A |
| 52 Week Low | $0.40 | $3.76 |
| 52 Week High | $2.47 | $46.80 |
Technical Indicators
Market Signals| Indicator | MOBX | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 80.94 |
| Support Level | $0.52 | $9.10 |
| Resistance Level | $0.61 | $10.45 |
| Average True Range (ATR) | 0.05 | 0.75 |
| MACD | 0.02 | 0.38 |
| Stochastic Oscillator | 59.66 | 92.29 |
Price Performance
Historical ComparisonAbout MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.